Bibliografia essenziale 1. Marcellin P, Buti M, Kraster Z, et al. Continued efficacy and safety thrugh 4 years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg negative patients with chronic hepatitis B (Study 102): preliminary analysis. AASLD 2010. Abstract 476. 2. Heathcote E, Gane EJ, de Man RA, et al. Long-term (4-year) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (Study 103): preliminary analysis. AASLD 2010. Abstract 477. 3. EACS Guidelines. Version 5. November 2009. 4. Di Marco V, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004;40:883-9. 5. Liaw YF, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2010; 53(1):62-72. 6. Fontana RJ. Entecavir in decompensated HBV cirrhosis: the future is looking brighter. J Hepatol. 2010;52:147–149. 7. Marzano A. The prevention of viral recurrence in the long term. Digestive and Liver Disease 2009;41S:S195–S197. 8. Teperman L, et al. Emtricitabine/tenofovir DF combination +/- HBIG post orthopic liver transplantation to prevent hepatitis B recurrence in patients with normal to moderate renal impairment: interim results. EASL 2010. Abstract 28.